B+
Bull case
25%
Probability
Target price
$96.00
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
ZTS
ZoetisANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The deterministic prior is positive, and a recovery in U.S. clinic demand alongside international osteoarthritis-product uptake could support a rerating.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Generic competition affected Cerenia and Convenia, and Librela sales were lower in the U.S. second quarter. [#SEC-8K-2026-08-06]
Momentum
78
Value
66
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $85.00 · Bull $96.00 · Bear $62.00Analysis 2026-10-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $87.82
Why
Momentum78 · Δ7d +18.9
Value66 · Δ7d -0.2
Sentiment55 · Δ7d -2.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.2.
Contradictions & invalidation
- • Generic competition affected Cerenia and Convenia, and Librela sales were lower in the U.S. second quarter. [#SEC-8K-2026-08-06]
- • Long-acting osteoarthritis launches and the broader pipeline have commercial promise, but future uptake and timing remain unquantified in the checked evidence.
- • The second-quarter guidance cut may prove persistent: management cited fewer clinic visits, pet-owner price sensitivity, competitive pressure and lower Librela sales.
Catalyst clock
2026-11-05
November 5 third-quarter results: test of U.S. companion-animal demand
Lead driver: Value · See fundamentals
Momentum
78
8% active weight
Current posture
7d trendSoftening
Δ7d
+18.9
Δ21d
+57.8
Value
66
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-1.7
Sentiment
55
45% active weight
Current posture
7d trendSoftening
Δ7d
-2.1
Δ21d
-
Why this grade
Composite grade A. Momentum 78.3 / Value 65.6 / Sentiment 55.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-18. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$85.00
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$62.00
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$33.48B
Beta
0.96
Shares Out
413.22M
P/E (TTM)
21.8
P/S (TTM)
6.07
P/FCF (TTM)
41.40
Rev YoY
-0.2%
EPS YoY
+1.5%
Gross Margin
+70.2%
Op Margin
+37.6%
Net Debt
$6.99B
Current Ratio
3.08
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data